| Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort KB Gecse, BD Lovász, K Farkas, J Banai, L Bene, B Gasztonyi, ... Journal of Crohn's and Colitis 10 (2), 133-140, 2016 | 177 | 2016 |
| Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in … LS Kiss, T Szamosi, T Molnar, P Miheller, L Lakatos, A Vincze, K Palatka, ... Alimentary pharmacology & therapeutics 34 (8), 911-922, 2011 | 151 | 2011 |
| Utility of serological markers in inflammatory bowel diseases: gadget or magic? M Papp, GL Norman, I Altorjay, PL Lakatos World journal of gastroenterology: WJG 13 (14), 2028, 2007 | 149 | 2007 |
| New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a … M Papp, I Altorjay, N Dotan, K Palatka, I Foldi, J Tumpek, S Sipka, ... American Journal of Gastroenterology 103 (3), 665-681, 2008 | 145 | 2008 |
| Immune dysfunction in cirrhosis N Sipeki, P Antal-Szalmas, PL Lakatos, M Papp World journal of gastroenterology: WJG 20 (10), 2564, 2014 | 128 | 2014 |
| Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections M Papp, Z Vitalis, I Altorjay, I Tornai, M Udvardy, J Harsfalvi, A Vida, ... Liver International 32 (4), 603-611, 2012 | 105 | 2012 |
| Incidence, Paris classification, and follow-up in a nationwide incident cohort of pediatric patients with inflammatory bowel disease KE Müller, PL Lakatos, A Arató, JB Kovács, Á Várkonyi, D Szucs, ... Journal of pediatric gastroenterology and nutrition 57 (5), 576-582, 2013 | 98 | 2013 |
| Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets B Mesko, S Poliskal, A Szegedi, Z Szekanecz, K Palatka, M Papp, L Nagy BMC medical genomics 3 (1), 15, 2010 | 90 | 2010 |
| Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype … M Papp, I Altorjay, GL Norman, Z Shums, K Palatka, Z Vitalis, I Foldi, ... Inflammatory bowel diseases 13 (8), 984-992, 2007 | 87 | 2007 |
| High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification? L Sandor Kiss, M Papp, B Dorottya Lovasz, Z Vegh, P Anna Golovics, ... Inflammatory bowel diseases 18 (9), 1647-1654, 2012 | 81 | 2012 |
| Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy T Molnár, PL Lakatos, K Farkas, F Nagy, Z Szepes, P Miheller, G Horváth, ... Alimentary pharmacology & therapeutics 37 (2), 225-233, 2013 | 76 | 2013 |
| Mucosal expression of claudins 2, 3 and 4 in proximal and distal part of duodenum in children with coeliac disease DN Szakál, H Győrffy, A Arató, Á Cseh, K Molnár, M Papp, A Dezsőfi, ... Virchows Archiv 456 (3), 245-250, 2010 | 76 | 2010 |
| Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with … T Szamosi, J Banai, L Lakatos, Z Czegledi, G David, F Zsigmond, ... European journal of gastroenterology & hepatology 22 (7), 872-879, 2010 | 75 | 2010 |
| Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not … PL Lakatos, I Altorjay, T Szamosi, K Palatka, Z Vitalis, J Tumpek, S Sipka, ... Inflammatory bowel diseases 15 (3), 365-374, 2009 | 74 | 2009 |
| ATG16L1 and IL23 receptor (IL23R) genes are associated with disease susceptibility in Hungarian CD patients PL Lakatos, T Szamosi, A Szilvási, E Molnar, L Lakatos, A Kovacs, ... Digestive and liver disease 40 (11), 867-873, 2008 | 71 | 2008 |
| Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe J Fernández, V Prado, J Trebicka, A Amoros, T Gustot, R Wiest, ... Journal of hepatology 70 (3), 398-411, 2019 | 70 | 2019 |
| Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease PL Lakatos, LS Kiss, K Palatka, I Altorjay, P Antal-Szalmas, E Palyu, ... Inflammatory bowel diseases 17 (3), 767-777, 2011 | 69 | 2011 |
| Increased levels of platelet activation markers are positively associated with carotid wall thickness and other atherosclerotic risk factors in obese patients É Csongrádi, B Nagy Jr, T Fulop, Z Varga, Z Karányi, MT Magyar, L Oláh, ... Thrombosis and haemostasis 106 (10), 683-692, 2011 | 63 | 2011 |
| Intestinal alkaline phosphatase in the colonic mucosa of children with inflammatory bowel disease K Molnár, Á Vannay, B Szebeni, NF Bánki, E Sziksz, Á Cseh, H Győrffy, ... World journal of gastroenterology: WJG 18 (25), 3254, 2012 | 60 | 2012 |
| Presence of anti-microbial antibodies in liver cirrhosis–a tell-tale sign of compromised immunity? M Papp, GL Norman, Z Vitalis, I Tornai, I Altorjay, I Foldi, M Udvardy, ... PLoS One 5 (9), e12957, 2010 | 58 | 2010 |
Nóra Sipeki MD, PhDUniversity of Debrecen; Department of Internal Medicine, Division of GastroenterologyE-mail megerősítve itt: med.unideb.hu
